专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009042607A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE 审中-公开
标题翻译：噻唑吡啶P13K抑制剂化合物及其使用方法
公开(公告)号：WO2009042607A1
公开(公告)日：2009-04-02
申请号：PCT/US2008/077394
申请日：2008-09-23
申请人： GENENTECH, INC. , F. HOFFMANN - LA ROCHE AG , CASTANEDO, Georgette, M. , GUNZNER, Janet, L. , MALESKY, Kimberly , MATHIEU, Simon , OLIVERO, Alan, G. , SUTHERLIN, Daniel, P. , WANG, Shumei , ZHU, Bing-yan , CHUCKOWREE, Irina , FOLKES, Adrian , OXENFORD, Sally , WAN, Nan Chi
发明人： CASTANEDO, Georgette, M. , GUNZNER, Janet, L. , MALESKY, Kimberly , MATHIEU, Simon , OLIVERO, Alan, G. , SUTHERLIN, Daniel, P. , WANG, Shumei , ZHU, Bing-yan , CHUCKOWREE, Irina , FOLKES, Adrian , OXENFORD, Sally , WAN, Nan Chi
IPC分类号： C07D513/04 , A61K31/519 , A61P35/00
CPC分类号： C07D513/04
摘要： Compounds of Formulas (Ia and Ib), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式（Ia和Ib）的化合物，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐可用于抑制脂质激酶（包括PI3K）和用于治疗由脂质激酶介导的癌症等疾病。公开了将式Ia和Ib化合物用于体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

2. 发明申请

WO2008070740A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE 审中-公开
标题翻译：磷酸三辛酯抑制剂化合物及其使用方法
公开(公告)号：WO2008070740A1
公开(公告)日：2008-06-12
申请号：PCT/US2007/086543
申请日：2007-12-05
申请人： PIRAMED LIMITED , GENENTECH, INC. , BAYLISS, Tracy , CHUCKOWREE, Irina , FOLKES, Adrian , OXENFORD, Sally , WAN, Nan, Chi , CASTANEDO, Georgette , GOLDSMITH, Richard , GUNZNER, Janet , HEFFRON, Tim , MATHIEU, Simon , OLIVERO, Alan , STABEN, Steven , SUTHERLIN, Daniel, P. , ZHU, Bing-Yan
发明人： BAYLISS, Tracy , CHUCKOWREE, Irina , FOLKES, Adrian , OXENFORD, Sally , WAN, Nan, Chi , CASTANEDO, Georgette , GOLDSMITH, Richard , GUNZNER, Janet , HEFFRON, Tim , MATHIEU, Simon , OLIVERO, Alan , STABEN, Steven , SUTHERLIN, Daniel, P. , ZHU, Bing-Yan
IPC分类号： C07D491/04 , C07D495/04 , A61K31/5377 , A61K31/519 , A61P35/00
CPC分类号： A61K31/5377 , A61K31/519 , C07D413/14 , C07D491/04 , C07D495/04
摘要： Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Insert Formula Ic and Id]
摘要翻译：式Ia-d的化合物，其中X是S或O，mor是吗啉基团，R3是单环杂芳基，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐可用于调节脂质激酶（包括PI3K）的活性，以及用于治疗脂质激酶介导的疾病如癌症。公开了使用式Ia-d化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种疾病的方法。 [插入公式Ic和Id]

3. 发明申请

WO2007127175A2 PHARMACEUTICAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2007127175A2
公开(公告)日：2007-11-08
申请号：PCT/US2007/009866
申请日：2007-04-24
申请人： PIRAMED LIMITED , GENENTECH, INC. , GOLDSMITH, Richard , FOLKES, Adrian , SHUTTLEWORTH, Stephen , CHUCKOWREE, Irina , OXENFORD, Sally , WAN, Nan Chi , CASTANEDO, Georgette , GUNZNER, Janet , HEFFRON, Tim , MATHIEU, Simon , OLIVERO, Alan , SUTHERLIN, Daniel, P. , ZHU, Bing-Yan
发明人： FOLKES, Adrian , SHUTTLEWORTH, Stephen , CHUCKOWREE, Irina , OXENFORD, Sally , WAN, Nan Chi , CASTANEDO, Georgette , GUNZNER, Janet , HEFFRON, Tim , MATHIEU, Simon , OLIVERO, Alan , SUTHERLIN, Daniel, P. , ZHU, Bing-Yan
CPC分类号： A61K31/5377 , A61K31/551 , A61K45/06 , C07D491/04 , C07D491/048 , C07D495/04
摘要： Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro , in situ , and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式Ia和Ib化合物及其立体异构体，几何异构体，互变异构体，溶剂化物，代谢物和药学上可接受的盐可用于抑制包括PI3K在内的脂质激酶，以及用于治疗诸如癌症脂质激酶。在体外，原位和体内诊断，预防或治疗这些哺乳动物疾病中使用式Ia和Ib化合物的方法细胞或相关的病理状况，都被公开。

4. 发明申请

WO2007127183A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 审中-公开
标题翻译：磷酸三钙激酶抑制剂化合物和含有它们的药物组合物
公开(公告)号：WO2007127183A1
公开(公告)日：2007-11-08
申请号：PCT/US2007/009880
申请日：2007-04-24
申请人： GENENTECH, INC. , PIRAMED LIMITED , CASTANEDO, Georgette , GOLDSMITH, Richard , GUNZNER, Janet , HEFFRON, Tim , MALESKY, Kimberly , MATHIEU, Simon , OLIVERO, Alan , SUTHERLIN, Daniel, P. , TSUI, Vickie , WANG, Shumei , WEISMANN, Christian , ZHU, Bing-Yan , DOTSON, Jennafer , FOLKES, Adrian , SHUTTLEWORTH, Stephen , OXENFORD, Sally , HANCOX, Tim , BAYLISS, Tracy
发明人： CASTANEDO, Georgette , GOLDSMITH, Richard , GUNZNER, Janet , HEFFRON, Tim , MALESKY, Kimberly , MATHIEU, Simon , OLIVERO, Alan , SUTHERLIN, Daniel, P. , TSUI, Vickie , WANG, Shumei , WEISMANN, Christian , ZHU, Bing-Yan , DOTSON, Jennafer , FOLKES, Adrian , SHUTTLEWORTH, Stephen , OXENFORD, Sally , HANCOX, Tim , BAYLISS, Tracy
IPC分类号： C07D491/04 , C07D495/04 , C07D519/00 , A61K31/519 , A61P35/00
CPC分类号： C07D491/04 , C07D495/04
摘要： Compounds of Formulas (Ia) and (Ib), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula (Ia) and (Ib) for i n vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式（Ia）和（Ib）的化合物，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和其药学上可接受的盐可用于抑制脂质激酶（包括PI3K）和用于治疗诸如由脂质激酶介导的癌症的疾病。公开了将式（Ia）和（Ib）的化合物用于体外，原位和生殖诊断，预防或治疗哺乳动物细胞或相关病理条件中的这些疾病的方法。

5. 发明申请

WO2009066084A1 2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS 审中-公开
标题翻译： 2-吗啉酰亚胺及其作为PI3激酶抑制剂的用途
公开(公告)号：WO2009066084A1
公开(公告)日：2009-05-28
申请号：PCT/GB2008/003910
申请日：2008-11-21
申请人： F. HOFFMANN-LA ROCHE AG , GENENTECH, INC. , CHUCKOWREE, Irina , FOLKES, Adrian , OXENFORD, Sally , OLIVERO, Alan , SUTHERLIN, Daniel, P. , ZHU, Bing-Yan
发明人： CHUCKOWREE, Irina , FOLKES, Adrian , OXENFORD, Sally , OLIVERO, Alan , SUTHERLIN, Daniel, P. , ZHU, Bing-Yan
IPC分类号： C07D239/42 , C07D239/47 , C07D239/48 , C07D401/14 , C07D403/14 , A61K31/506 , A61P35/00
CPC分类号： C07D239/48 , C07D239/42 , C07D239/47 , C07D401/14 , C07D403/14 , C07D413/14
摘要： Morpholino pyrimidines of formula (I): wherein R 1 is selected from -Y-R 6 and -NR 4 R 5 ; R 2 is a N-containing monocyclic heteroaryl group which is selected from pyridyl, isoxazolyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, furanyl, thienyl, triazolyl and tetrazolyl and which is unsubstituted or substituted by halo, -CN, -NR 10 R 11 , -OR 10 , -C(O)R 10 , -NR 10 C(O)R 11 , - N(C(O)R 11 ) 2 , -NR 10 C(O)NR 10 R 11 , -SO 2 R 10 R 11 , -SO 2 NR 10 R 11 , -C(=O)OR 10 , -C(=O)NR 10 R 11 , halo-C 1 -C 6 alkyl and unsubstituted C 1 -C 12 alkyl; R 3 is selected from H, C 1 -C 6 alkyl and C 1 -C 6 alkoxy; Y is selected from a direct bond, -(CR 2 ) m -, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, -(CR 2 ) p -O-(CR 2 ) t -, -(CR 2 ) p -NR-(CR 2 ) t , -(CR 2 ) p -NR-(CR 2 ) n -C(O)-, -(CR 2 ) p -NR-C(O)- (CR 2 ) n -, -(CR 2 ) p -C(O)-NR-(CR 2 ) t , -(CR 2 ) p -C(O)-(CR 2 ) n -NR-(CR 2 ) t ,- and -(CR 2 ) p - C(O)-(CR 2 ) n -; R 6 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic ring, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted, C 1 -C 6 alkyl, -NR 2 , -OR, -NR(CO)R and - C(O)NR 2 ; R 4 and R 5 , which are the same or different, are both C 1 -C 6 alkyl which is unsubstituted or substituted, or R 4 and R 5 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted; each R, which are the same or different when more than one is present in a given group, is independently H, C 1 -C 6 alkyl which is unsubstituted or substituted or a 5- to 12-membered aryl or heteroaryl group which is unsubstituted or substituted; R 10 and R 11 , which are the same or different, are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 3 -C 8 cycloalkyl; n is 0 or an integer of 1 to 6; m is an integer of 1 to 6; p is 0 or an integer of 1 to 6; and t is 0 or an integer of 1 to 6, with the proviso that t is an integer of 2 to 6 when R 6 is linked to Y through a constituent O or N atom of R 6 ; and the pharmaceutically acceptable salts thereof, subject to various provisos, have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly that associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
摘要翻译：式（I）的吗啉代嘧啶：其中R1选自-Y-R6和-NR4R5; R2是选自吡啶基，异恶唑基，咪唑基，吡唑基，吡咯基，噻唑基，哒嗪基，嘧啶基，吡嗪基，恶唑基，呋喃基，噻吩基，三唑基和四唑基中的含氮单环杂芳基，其未被取代或被卤素取代， CN，-NR10R11，-OR10，-C（O）R10，-NR10C（O）R11，-N（C（O）R11）2，-NR10C（O）NR10R11，-SO2R10R11，-SO2NR10R11，-C（= O）OR 10，-C（= O）NR 10 R 11，卤代-C 1 -C 6烷基和未取代的C 1 -C 12烷基; R 3选自H，C 1 -C 6烷基和C 1 -C 6烷氧基; Y选自直接键， - （CR2）m-，C2-C6亚烯基，C2-C6亚炔基， - （CR2）pO-（CR2）t-， - （CR2）p-NR-（CR2） - （CR2）p-NR-（CR2）nC（O） - ， - （CR2）p-NR-C（O） - （CR2）n - ， - （CR2）pC（O）-NR-（CR2）（CR2）pC（O） - （CR2）n-NR-（CR2）t， - 和 - （CR2）p- C（O） - （CR2） R 6选自不饱和的5至12元碳环或杂环，未取代或取代的饱和的5-，6-或7-元含氮杂环基，C 1 -C 6烷基，-NR 2，-OR， -NR（CO）R和-C（O）NR 2; R 4和R 5相同或不同，为未取代或取代的C 1 -C 6烷基，或者R 4和R 5与它们所连接的氮原子一起形成饱和的5-，6-或7- 未取代或取代的N，N元杂环基; 当在给定基团中存在多于一个时，各R相同或不同，独立地为H，未取代或取代的C 1 -C 6烷基或未被取代或取代的5至12元芳基或杂芳基 ; R10和R11相同或不同，独立地选自H，C1-C6烷基，C2-C6烯基，C2-C6炔基和C3-C8环烷基; n为0或1〜6的整数， m为1〜6的整数。 p为0或1〜6的整数; 并且当R 6通过R6的组分O或N原子连接到Y时，t为0或1-6的整数，条件是t为2至6的整数; 和其药学上可接受的盐，具有各种条件，具有作为PI3K抑制剂的活性，因此可用于治疗由异常细胞生长，功能或行为引起的疾病和障碍，特别是与PI3激酶如癌症，免疫疾病心血管疾病，病毒感染，炎症，代谢/内分泌紊乱和神经障碍。还描述了合成化合物的方法。

6. 发明申请

WO2009146406A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE 审中-公开
标题翻译： PURINE PI3K抑制剂化合物及其使用方法
公开(公告)号：WO2009146406A1
公开(公告)日：2009-12-03
申请号：PCT/US2009/045603
申请日：2009-05-29
申请人： GENENTECH, INC. , F. HOFFMANN-LA ROCHE AG , CASTANEDO, Georgette , CHUCKOWREE, Irina , FOLKES, Adrian , SUTHERLIN, Daniel, P. , WAN, Nan Chi
发明人： CASTANEDO, Georgette , CHUCKOWREE, Irina , FOLKES, Adrian , SUTHERLIN, Daniel, P. , WAN, Nan Chi
IPC分类号： C07D473/32 , A61P35/00 , A61K31/52
CPC分类号： C07D473/32
摘要： Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I的嘌呤化合物，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和其药学上可接受的盐可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗诸如由脂质激酶介导的癌症。公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

7. 发明申请

WO2009123971A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE 审中-公开
标题翻译：苯并吡喃和苯唑西林PI3K抑制剂化合物及其使用方法
公开(公告)号：WO2009123971A1
公开(公告)日：2009-10-08
申请号：PCT/US2009/038795
申请日：2009-03-30
申请人： GENENTECH, INC. , F. HOFFMANN- LA ROCHE AG , DO, Steven , GOLDSMITH, Richard , HEFFRON, Tim , KOLESNIKOV, Aleksandr , STABEN, Steven , OLIVERO, Alan, G. , SIU, Michael , SUTHERLIN, Daniel, P. , ZHU, Bing-yan , GOLDSMITH, Paul , BAYLISS, Tracy , FOLKES, Adrian , PEGG, Neil
发明人： DO, Steven , GOLDSMITH, Richard , HEFFRON, Tim , KOLESNIKOV, Aleksandr , STABEN, Steven , OLIVERO, Alan, G. , SIU, Michael , SUTHERLIN, Daniel, P. , ZHU, Bing-yan , GOLDSMITH, Paul , BAYLISS, Tracy , FOLKES, Adrian , PEGG, Neil
IPC分类号： C07D495/04 , C07D513/04 , A61K31/38 , A61K31/429 , A61P35/00
CPC分类号： C07F5/02 , A61K31/381 , A61K31/4155 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/4436 , A61K31/496 , A61K31/53 , C07D495/04 , C07D495/14 , C07D513/14
摘要： Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I和II的苯并吡喃和苯并辛菌素化合物，包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗疾病如癌症由脂质激酶介导。公开了使用式I和II的化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

8. 发明申请

WO2009126863A3 PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING 审中-公开
公开(公告)号：WO2009126863A3
公开(公告)日：2009-10-15
申请号：PCT/US2009/040165
申请日：2009-04-10
申请人： GENENTECH, INC. , CURIS, INC. , GUNZNER, Janet, L. , SUTHERLIN, Daniel, P. , STANLEY, Mark, S. , BAO, Liang , CASTANEDO, Georgette , LALONDE, Rebecca, L. , WANG, Shumei , REYNOLDS, Mark, E. , SAVAGE, Scott, J. , MALESKY, Kimberly , DINA, Michael, S.
发明人： GUNZNER, Janet, L. , SUTHERLIN, Daniel, P. , STANLEY, Mark, S. , BAO, Liang , CASTANEDO, Georgette , LALONDE, Rebecca, L. , WANG, Shumei , REYNOLDS, Mark, E. , SAVAGE, Scott, J. , MALESKY, Kimberly , DINA, Michael, S.
IPC分类号： C07D403/14 , C07D403/06 , C07D213/06
摘要： The invention provides novel inhibitors of hedgehog signaling that are useful as s therapeutic agent for treating malignancies where the compounds have the general formula (I): where A, X, Y R 1, R 2, R 3, R 4, m and n are as described herein.

9. 发明申请

WO2006105386A1 CDK2 INHIBITORS 审中-公开
标题翻译： CDK2抑制剂
公开(公告)号：WO2006105386A1
公开(公告)日：2006-10-05
申请号：PCT/US2006/011880
申请日：2006-03-29
申请人： GENENTECH, INC. , CASTANEDO, Georgette, M. , STANLEY, Mark, S. , SUTHERLIN, Daniel, P. , TSUI, Vickie, Hsiao-Wei
发明人： CASTANEDO, Georgette, M. , STANLEY, Mark, S. , SUTHERLIN, Daniel, P. , TSUI, Vickie, Hsiao-Wei
IPC分类号： C07K5/06 , A61P35/00 , C07C233/61
CPC分类号： C07K5/06026 , A61K38/00 , C07K5/06 , C07K5/0606 , C07K5/06095 , C07K5/06191
摘要： The invention provides novel inhibitors of Cdk2 that are useful as therapeutic agents for treating malignancies where the compounds have the general Formula I: (I) wherein R i , R 2 , R 2 -, R 3 , R 3 , R 4 , X Y, Z i , Z 2 and Z 3 are as described herein.
摘要翻译：本发明提供新的Cdk2抑制剂，其可用作治疗恶性肿瘤的治疗剂，其中化合物具有通式I：（I）其中R 1，R 2，R 2， R 3，R 3，R 3，R 4，XY，Z 1，N 2， >，Z 2和Z 3如本文所述。

10. 发明申请

WO2007059157A1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING 审中-公开
标题翻译：双嘧达莫抑制剂信号传导信号
公开(公告)号：WO2007059157A1
公开(公告)日：2007-05-24
申请号：PCT/US2006/044240
申请日：2006-11-14
申请人： GENENTECH, INC. , CURIS, INC. , GOLDSMITH, Richard, A. , SUTHERLIN, Daniel, P. , ROBARGE, Kirk, D. , OLIVERO, Alan, G.
发明人： GOLDSMITH, Richard, A. , SUTHERLIN, Daniel, P. , ROBARGE, Kirk, D. , OLIVERO, Alan, G.
IPC分类号： C07D213/82 , C07D239/28 , C07D277/56 , C07D401/12 , C07D417/12 , C07D231/14 , A61K31/167 , A61K31/496 , A61K31/444 , A61K31/44 , A61K31/4545 , A61K31/4164 , A61K31/4196 , A61K31/4453 , A61K31/5375
CPC分类号： A61K31/167 , A61K31/381 , A61K31/4164 , A61K31/4196 , A61K31/426 , A61K31/433 , A61K31/44 , A61K31/444 , A61K31/4453 , A61K31/4545 , A61K31/496 , A61K31/505 , A61K31/5375 , A61K31/538 , C07D213/82 , C07D231/14 , C07D233/06 , C07D239/28 , C07D249/08 , C07D265/36 , C07D277/56 , C07D285/06 , C07D295/155 , C07D307/68 , C07D333/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D417/12
摘要： The invention provides inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula (I), wherein ring A, ring B, R 1 , R 2 , R 3 , R 4 , R 5 , m and n are as defined herein.
摘要翻译：本发明提供了可用作治疗恶性肿瘤的治疗剂的刺猬蛋白信号传导抑制剂，其中化合物具有通式（I），其中环A，环B，R 1，R 2 R 3，R 3，R 5，m和n如本文所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式